https://www.cancernetwork.com/view/practice-changes-key-takeaways-and-closing-remarks2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bdd3ddf809bee6fd691f5171ec241ab17a25cf2d-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405903658112 https://www.cancernetwork.com/view/triaging-post-car-t-complications-in-two-practical-scenarios2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bdd3ddf809bee6fd691f5171ec241ab17a25cf2d-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405904825112 https://www.cancernetwork.com/view/recognizing-delayed-neurotoxicity-and-immune-effector-cell-enterocolitis2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bdd3ddf809bee6fd691f5171ec241ab17a25cf2d-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405903942112 https://www.cancernetwork.com/view/long-term-monitoring-prophylaxis-and-vaccination-after-cilta-cel2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bdd3ddf809bee6fd691f5171ec241ab17a25cf2d-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405903746112 https://www.cancernetwork.com/view/day-28-discharge-and-transition-to-shared-community-care2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bdd3ddf809bee6fd691f5171ec241ab17a25cf2d-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405903462112 https://www.cancernetwork.com/view/timing-referral-holding-therapy-and-bridging-therapy-definitions2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bdd3ddf809bee6fd691f5171ec241ab17a25cf2d-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405903380112 https://www.cancernetwork.com/view/building-referral-relationships-with-community-oncology-practices2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bdd3ddf809bee6fd691f5171ec241ab17a25cf2d-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405905134112 https://www.cancernetwork.com/view/ciltacabtagene-autoleucel-manufacturing-debulking-and-bridging-in-multiple-myeloma2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bdd3ddf809bee6fd691f5171ec241ab17a25cf2d-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405903171112 https://www.cancernetwork.com/view/referral-barriers-to-chimeric-antigen-receptor-t-cell-therapy-in-multiple-myeloma2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bdd3ddf809bee6fd691f5171ec241ab17a25cf2d-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405904241112 https://www.cancernetwork.com/view/excaliber-rrmm-iberdomide-in-relapsed-refractory-multiple-myeloma2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d9ad7ca9278f1ae7750ece9eb0ffa26d246d4ccb-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405963822112 https://www.cancernetwork.com/view/follow-up-after-a-one-time-therapy-and-shared-care-with-community-practices2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cce3ca0db6b78145397ec35ede82b90cd456b9f3-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405967078112 https://www.cancernetwork.com/view/introduction-to-celmods-in-relapsed-refractory-multiple-myeloma2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d9ad7ca9278f1ae7750ece9eb0ffa26d246d4ccb-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405964201112 https://www.cancernetwork.com/view/cartitude-2-cohort-a-follow-up-data-and-preparing-patients-for-car-tcell-therapy2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cce3ca0db6b78145397ec35ede82b90cd456b9f3-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405969945112 https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-case-based-discussion-the-comorbid-higher-risk-patient-and-program-conclusions2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e385b3597c35077e501588824deb6d77b414a42b-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405973195112 https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-case-based-discussion-the-fit-immunotherapy-eligible-patient-in-second-line2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e385b3597c35077e501588824deb6d77b414a42b-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405972711112 https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-case-based-discussion-rapidly-progressive-earlier-relapse-disease2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e385b3597c35077e501588824deb6d77b414a42b-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405973585112 https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-debate-contextualizing-safety-and-sequencing-bcma-directed-therapies2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e385b3597c35077e501588824deb6d77b414a42b-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405972507112 https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-debate-treatment-selection-between-car-t-cell-and-bispecific-approaches-in-second-line-disease2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e385b3597c35077e501588824deb6d77b414a42b-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405973288112 https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-safety-and-real-world-management-of-bcma-directed-therapies2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e385b3597c35077e501588824deb6d77b414a42b-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405972993112 https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-cartitude-4-long-term-outcomes-and-treatment-free-remission-with-cilta-cel2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e385b3597c35077e501588824deb6d77b414a42b-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405973584112 https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-majestec-9-and-teclistamab-monotherapy-in-lenalidomide-and-anti-cd38-double-refractory-disease2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e385b3597c35077e501588824deb6d77b414a42b-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405973096112 https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-real-world-treatment-patterns-attrition-and-the-case-for-earlier-bcma-directed-therapy2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e385b3597c35077e501588824deb6d77b414a42b-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405973381112 https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-majestec-3-and-the-bispecific-antibody-approach-in-earlier-relapse-disease2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e385b3597c35077e501588824deb6d77b414a42b-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405973194112 https://www.cancernetwork.com/view/shared-decision-making-in-relapsed-refractory-multiple-myeloma2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ee2dcebb52338b07c0f0b1feb3d79bd789bdec59-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403599074112 https://www.cancernetwork.com/view/copernicus-design-prophylaxis-counseling-and-brain-metastases2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f262d25b087baecf6f9a841774228a3a1b8dd385-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405489065112 https://www.cancernetwork.com/view/dreamm-7-design-efficacy-and-safety2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5d85b183a65b796025d1b612fee5278201cf7a5c-774x432.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405742045112 https://www.cancernetwork.com/view/molecular-testing-turnaround-time-and-response-assessment2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1a2a03afd454f318c637036bd15889e30b3fd563-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405917913112 https://www.cancernetwork.com/view/evolving-treatment-goals-in-multiple-myeloma2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/861929e27d571698cfbaedb08dc72bd6bf0adfb8-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405749544112 https://www.cancernetwork.com/view/menin-inhibitor-landscape-in-npm1-mutated-and-kmt2a-rearranged-aml2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1a2a03afd454f318c637036bd15889e30b3fd563-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405919954112 https://www.cancernetwork.com/view/evolution-of-frontline-therapy-in-multiple-myeloma2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/861929e27d571698cfbaedb08dc72bd6bf0adfb8-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405749545112 https://www.cancernetwork.com/view/self-advocacy-and-treatment-decisions-in-relapsed-refractory-multiple-myeloma2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ee2dcebb52338b07c0f0b1feb3d79bd789bdec59-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403598579112 https://www.cancernetwork.com/view/extended-anticoagulation-and-skin-care-adherence-on-amivantamab2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f262d25b087baecf6f9a841774228a3a1b8dd385-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405490318112 https://www.cancernetwork.com/view/sequencing-fgfr2-inhibitors-in-previously-treated-cholangiocarcinoma2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c9a5184869b1549f49e584933622a660ffdba996-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405745893112 https://www.cancernetwork.com/view/patient-selection-for-belantamab-mafodotin2026-09-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5d85b183a65b796025d1b612fee5278201cf7a5c-774x432.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405742810112 https://www.cancernetwork.com/view/lirafugratinib-approval-adds-a-third-fgfr2-inhibitor-in-cholangiocarcinoma2026-09-29https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3f7c04b33626ec6e6a1ace83c981e5c811592693-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405745609112 https://www.cancernetwork.com/view/when-single-fraction-srs-still-makes-sense-for-resected-brain-metastases2026-09-29https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6ef85fa1e255f6a8e2b33c9ac2f54aff120abb04-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405742691112 https://www.cancernetwork.com/view/where-mrd-testing-fits-into-myeloma-s-treatment-and-regulatory-landscape2026-09-29https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6d5b5776983f3642970057d4e322e81a12874e5a-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405741838112 https://www.cancernetwork.com/view/dreamm-7-study-design-and-the-rationale2026-09-29https://cdn.sanity.io/images/0vv8moc6/cancernetwork/627864ea167ec133de98c6d9e9840ec4ee33b0f0-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405503300112 https://www.cancernetwork.com/view/proton-hypofractionated-radiation-shine-in-nonoperative-cholangiocarcinoma2026-09-29https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5e61ec0d1be800c84c2fc547f3b2a694e9c511ea-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405628596112 https://www.cancernetwork.com/view/from-accelerated-approval-to-reapproval-of-belantamab-mafodotin2026-09-29https://cdn.sanity.io/images/0vv8moc6/cancernetwork/627864ea167ec133de98c6d9e9840ec4ee33b0f0-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405503300112 https://www.cancernetwork.com/view/fractionated-srs-tops-single-fraction-srs-after-brain-metastasis-resection2026-09-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/889810371e1fb856d9a307632a349d6df665c1d3-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405747150112 https://www.cancernetwork.com/view/fractionated-srs-should-be-standard-of-care-after-brain-metastasis-surgery2026-09-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7fa3d342c4c95ea0a1413dd86b0d8ea63afa5a3e-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405747150112 https://www.cancernetwork.com/view/first-in-human-jyoti-malhotra-md-mph-on-phase-i-trials-lung-cancer-in-2026-and-yale2026-09-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f9a7cc749eadff17b0e7e6cc94fdd087f4b96b6b-1280x720.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405199485112 https://www.cancernetwork.com/view/distal-extrahepatic-cholangiocarcinoma-may-gain-from-neoadjuvant-radiation2026-09-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/84384b44a90cb0051a8d5d513cfba4037d78cabd-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405627141112 https://www.cancernetwork.com/view/the-value-of-testing-in-the-expanding-egfr-exon-20-insertion-landscape2026-09-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/004ff953e4f840a56d8ae229f2442e2d4a15c412-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405558472112 https://www.cancernetwork.com/view/flaura2-survival-and-limits-of-cross-trial-comparison2026-09-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/215de075d86f817fc65d871aa96deb9aa1b01f42-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405197070112 https://www.cancernetwork.com/view/choosing-between-regimens-future-directions-and-key-takeaways2026-09-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3c7a8b7d8cc2f7826679acabaa26445fe9d8d8d2-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403336165112 https://www.cancernetwork.com/view/emerging-clinical-evidence-and-future-role-of-celmods-in-multiple-myeloma2026-09-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/fe82f7f4ac35486c484a02403932764cecd8188f-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404154827112 https://www.cancernetwork.com/view/weighing-toxicity-against-survival-benefit-in-counseling2026-09-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/215de075d86f817fc65d871aa96deb9aa1b01f42-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405198221112 https://www.cancernetwork.com/view/neoadjuvant-radiation-may-improve-tolerability-in-cholangiocarcinoma2026-09-27https://cdn.sanity.io/images/0vv8moc6/cancernetwork/62a7e73c4c70f44cc45659cbeaffc8616924e122-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405628597112 https://www.cancernetwork.com/view/how-are-personalized-frontline-multiple-myeloma-treatments-evolving-2026-09-27https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f210b1ceacf5527a14861f64ce630bdeeda8b1f8-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405634272112 https://www.cancernetwork.com/view/applying-the-ims-imwg-definition-of-cure-in-community-myeloma-practice2026-09-27https://cdn.sanity.io/images/0vv8moc6/cancernetwork/48439a1604f17ca075744a7cfe75f2c2dd376cfe-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405584695112 https://www.cancernetwork.com/view/how-academic-community-oncologists-improve-access-to-new-myeloma-therapies2026-09-26https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3bd3dc1bf8e3b75e156e8da5af687baa1dc431b2-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405633289112 https://www.cancernetwork.com/view/managing-sustained-mrd-negativity-after-multiple-myeloma-therapy-ends2026-09-26https://cdn.sanity.io/images/0vv8moc6/cancernetwork/24cb16912fd4483e664cb755c20996a4ddce5abb-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405584110112 https://www.cancernetwork.com/view/switching-to-sc-dosing-and-considering-pro-data-for-amivantamab-in-nsclc2026-09-25https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ca6c27b20736ac014aa74e5f17df5aed01606061-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405557887112 https://www.cancernetwork.com/view/soho-02-trial-will-confirm-sevabertinib-s-frontline-nsclc-benefit2026-09-24https://cdn.sanity.io/images/0vv8moc6/cancernetwork/71a8112baa9904d84c85cfd6d45b880cd000663c-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405368661112 https://www.cancernetwork.com/view/how-kras-g12c-data-should-shape-combination-trial-design2026-09-24https://cdn.sanity.io/images/0vv8moc6/cancernetwork/a16b639ac83a9283054e0682360291bab6d58ac1-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405430914112 https://www.cancernetwork.com/view/emerging-endocrine-doublets-and-serial-esr1-testing-in-hr-her2-mbc2026-09-24https://cdn.sanity.io/images/0vv8moc6/cancernetwork/896dcfc5c9d747d7a3dbc3f2c5b5dfd59836f951-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404816996112 https://www.cancernetwork.com/view/the-case-for-frontline-zongertinib-in-her2-mutant-nsclc2026-09-24https://cdn.sanity.io/images/0vv8moc6/cancernetwork/767eb7ff2e49c2ee2198847a60b02456e347745a-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405441673112 https://www.cancernetwork.com/view/anselamimab-s-kappa-subgroup-signal-could-reshape-anti-fibril-therapy-in-al-amyloidosis2026-09-24https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6f61159b89299e9a0c20a33ce7ce04de5d0ec29f-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405489669112 https://www.cancernetwork.com/view/acting-on-a-her2-result-and-navigating-access-to-therapy2026-09-24https://cdn.sanity.io/images/0vv8moc6/cancernetwork/767eb7ff2e49c2ee2198847a60b02456e347745a-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405441987112 https://www.cancernetwork.com/view/patient-centered-treatment-transitions-in-hr-her2-mbc2026-09-24https://cdn.sanity.io/images/0vv8moc6/cancernetwork/896dcfc5c9d747d7a3dbc3f2c5b5dfd59836f951-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404817484112 https://www.cancernetwork.com/view/defining-the-role-of-bispecifics-in-relapsed-waldenstr-m-macroglobulinemia2026-09-23https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d0fb5c62f763981e3754c786a12f9c9d0972b73d-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405486692112 https://www.cancernetwork.com/view/why-kras-g12c-may-drive-a-survival-benefit-with-cemiplimab-in-nsclc2026-09-23https://cdn.sanity.io/images/0vv8moc6/cancernetwork/a691e8a61d71cbdd40502d1dff007ab9fc616a3b-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405430913112 https://www.cancernetwork.com/view/advocacy-and-support-in-relapsed-refractory-multiple-myeloma2026-09-23https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ee2dcebb52338b07c0f0b1feb3d79bd789bdec59-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403597533112 https://www.cancernetwork.com/view/how-bundled-prophylaxis-changes-first-line-amivantamab-use2026-09-23https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f262d25b087baecf6f9a841774228a3a1b8dd385-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405439947112 https://www.cancernetwork.com/view/background-for-subcutaneous-amivantamab-plus-lazertinib-in-nsclc2026-09-23https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f262d25b087baecf6f9a841774228a3a1b8dd385-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405440127112 https://www.cancernetwork.com/view/how-sevabertinib-stacks-up-against-other-her2-directed-nsclc-options2026-09-23https://cdn.sanity.io/images/0vv8moc6/cancernetwork/89b851255fff8755ae971c4216eb64222bceadaa-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405368770112 https://www.cancernetwork.com/view/balancing-quality-of-life-and-treatment-goals-in-relapsed-refractory-multiple-myeloma2026-09-23https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ee2dcebb52338b07c0f0b1feb3d79bd789bdec59-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403598201112 https://www.cancernetwork.com/view/distinguishing-her2-mutations-from-amplification-in-nsclc-testing2026-09-22https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6d4f553da9e4402b769225489bed14624f29e92a-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405370327112 https://www.cancernetwork.com/view/overall-survival-with-amivantamab-plus-lazertinib-in-mariposa2026-09-21https://cdn.sanity.io/images/0vv8moc6/cancernetwork/215de075d86f817fc65d871aa96deb9aa1b01f42-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405198513112 https://www.cancernetwork.com/view/celmods-after-t-cell-engaging-therapy-in-multiple-myeloma2026-09-21https://cdn.sanity.io/images/0vv8moc6/cancernetwork/fe82f7f4ac35486c484a02403932764cecd8188f-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404156403112 https://www.cancernetwork.com/view/clinical-implications-open-questions-and-looking-ahead2026-09-21https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3c7a8b7d8cc2f7826679acabaa26445fe9d8d8d2-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403338019112 https://www.cancernetwork.com/view/iberdomide-based-treatment-in-lenalidomide-refractory-multiple-myeloma2026-09-21https://cdn.sanity.io/images/0vv8moc6/cancernetwork/fe82f7f4ac35486c484a02403932764cecd8188f-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404153052112 https://www.cancernetwork.com/view/how-first-line-treatment-of-egfr-mutated-nsclc-has-changed2026-09-21https://cdn.sanity.io/images/0vv8moc6/cancernetwork/215de075d86f817fc65d871aa96deb9aa1b01f42-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405196853112 https://www.cancernetwork.com/view/screening-for-chip-mutations-to-guide-car-t-cell-candidacy-in-lymphoma2026-09-19https://cdn.sanity.io/images/0vv8moc6/cancernetwork/4d350716b8bdae6dead151f209f5e151b135c175-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405144732112 https://www.cancernetwork.com/view/subcutaneous-amivantamab-combo-is-a-clear-new-standard-in-egfr-nsclc2026-09-18https://cdn.sanity.io/images/0vv8moc6/cancernetwork/b57b3dd460a29c39b03564edf303b00b754f683b-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405150278112 https://www.cancernetwork.com/view/navigating-transplant-strategy-for-partial-responders-in-t-cell-lymphoma2026-09-17https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0b05604b9758d6a8bab83b939f8ab3069631c496-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=undefined https://www.cancernetwork.com/view/differentiating-mutagenesis-from-genotoxic-risk-in-secondary-malignancies2026-09-17https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bfdbe86ad35a1e9decf152f81d4c411662908715-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405143857112 https://www.cancernetwork.com/view/dual-biomarkers-and-treatment-sequencing-in-hr-her2-mbc2026-09-17https://cdn.sanity.io/images/0vv8moc6/cancernetwork/896dcfc5c9d747d7a3dbc3f2c5b5dfd59836f951-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404816799112 https://www.cancernetwork.com/view/esr1-directed-treatment-options-in-hr-her2-mbc2026-09-17https://cdn.sanity.io/images/0vv8moc6/cancernetwork/896dcfc5c9d747d7a3dbc3f2c5b5dfd59836f951-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404817982112 https://www.cancernetwork.com/view/subcutaneous-amivantamab-cuts-infusion-time-in-nsclc-care2026-09-17https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d2d98ac90980aa13d59ee50178d77c51806d2001-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405150854112 https://www.cancernetwork.com/view/paloma-2-shows-improved-survival-vs-historical-iv-amivantamab-data2026-09-16https://cdn.sanity.io/images/0vv8moc6/cancernetwork/4e0c32af4c3b2f8170e8d4d4bf66ed10b1ea2bbc-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405150379112 https://www.cancernetwork.com/view/the-tcl-subtypes-that-warrant-upfront-allogeneic-transplant-consolidation2026-09-16https://cdn.sanity.io/images/0vv8moc6/cancernetwork/a97408b3cd9531a18e632fdc2bec6d13ca62c19c-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405047396112 https://www.cancernetwork.com/view/maintaining-quality-of-life-during-relapsed-refractory-multiple-myeloma-treatment2026-09-16https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ee2dcebb52338b07c0f0b1feb3d79bd789bdec59-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403598886112 https://www.cancernetwork.com/view/psychosocial-support-for-treatment-related-challenges-in-relapsed-refractory-multiple-myeloma2026-09-16https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ee2dcebb52338b07c0f0b1feb3d79bd789bdec59-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403598202112 https://www.cancernetwork.com/view/closing-reflections-on-bcma-directed-therapy-in-relapsed-refractory-multiple-myeloma2026-09-16https://cdn.sanity.io/images/0vv8moc6/cancernetwork/50171b46bbf140c9a61bcc8068647893cf610187-886x498.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6402775992112 https://www.cancernetwork.com/view/does-venetoclax-azacitidine-make-chemotherapy-obsolete-in-aml-2026-09-16https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e0d17f18069a586eeabefb1fccdf198953d1ff78-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404838474112 https://www.cancernetwork.com/view/how-does-azacitidine-venetoclax-impact-hospital-burden-in-aml-2026-09-15https://cdn.sanity.io/images/0vv8moc6/cancernetwork/a363aaca29b7c66d62bbfcf4b817c2d90a62d7ba-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404839280112 https://www.cancernetwork.com/view/why-a-gentler-aml-regimen-outperforming-chemotherapy-matters2026-09-15https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7eefd3da3623d88420407bbd883dd30e6cf7e68c-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404837074112 https://www.cancernetwork.com/view/tourmaline-durvalumab-safety-with-gemcitabine-based-chemotherapy-backbones2026-09-15https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3c7a8b7d8cc2f7826679acabaa26445fe9d8d8d2-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403338408112 https://www.cancernetwork.com/view/iberdomide-in-lenalidomide-refractory-multiple-myeloma2026-09-14https://cdn.sanity.io/images/0vv8moc6/cancernetwork/fe82f7f4ac35486c484a02403932764cecd8188f-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404154065112 https://www.cancernetwork.com/view/emerging-celmods-in-multiple-myeloma2026-09-14https://cdn.sanity.io/images/0vv8moc6/cancernetwork/fe82f7f4ac35486c484a02403932764cecd8188f-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404154226112 https://www.cancernetwork.com/view/epcore-fl-1-shows-efficacy-and-safety-of-epcoritamab-combination-therapy2026-09-11https://cdn.sanity.io/images/0vv8moc6/cancernetwork/aa93eb34df0e8905f4e5d86935fbeba9aad866fb-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404949979112 https://www.cancernetwork.com/view/ofirnoflast-shows-activity-across-high-risk-mutated-mds-subtypes2026-09-11https://cdn.sanity.io/images/0vv8moc6/cancernetwork/49cd8ca38981dd7316f1aa620b6aa80451997027-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404906164112 https://www.cancernetwork.com/view/what-faster-pharmacokinetics-mean-for-detecting-small-brain-metastases2026-09-11https://cdn.sanity.io/images/0vv8moc6/cancernetwork/69813804b386d3c0e829a9c80c9aca461940d174-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404550166112 https://www.cancernetwork.com/view/early-camizestrant-switching-has-a-learning-curve-before-becoming-standard2026-09-11https://cdn.sanity.io/images/0vv8moc6/cancernetwork/72b462befbb40df24fc633b2405cf687a60df166-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404831710112 https://www.cancernetwork.com/view/novel-agent-validates-hepicidin-agonist-approach-in-polycythemia-vera2026-09-11https://cdn.sanity.io/images/0vv8moc6/cancernetwork/4430482bd9628b03abfd9167634c1f001350e086-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404892303112 https://www.cancernetwork.com/view/novel-myelofibrosis-drug-is-versatile-for-managing-anemia2026-09-10https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f1a2b0a988cd06fad5e107cf4f74212040586b91-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404893410112 https://www.cancernetwork.com/view/early-camizestrant-is-favored-upon-esr1-mutation-emergence-in-breast-cancer2026-09-10https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d3b1f8775bd75aaf9fa6601660bd4e93a5816a94-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404832990112